Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 70

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 70
---
 We can no longer                                                            
 use EGC exemptions for test-the-waters communications or scaled executive compensation disclosures. |

Our transition from EGC status became effective on December 31, 2024, as we exceeded the five-year anniversary of our initial public offering. However, we continue to qualify as a smaller reporting company under SEC rules and as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which permits certain scaled disclosures but does not alleviate all obligations triggered by the loss of EGC status. Compliance with these requirements may strain our financial and operational resources and could make us less attractive to investors accustomed to EGC reporting standards. Our common stock price may be volatile and as a result you could lose all or part of your investment. In addition to volatility associated with equity securities in general, the value of your investment could decline due to the impact of any of the following factors upon the market price of our shares of common stock:

| ● | disappointing results from our development efforts; |

| ● | decline in demand for our shares of common stock; |

| ● | downward revisions in securities analysts’ estimates 
 or changes in general market conditions;             |

| ● | technological innovations by competitors or in competing 
 products;                                                |

| ● | investor perception of our industry or our prospects; and |

| ● | general economic trends. |

Stock markets in general have experienced extreme price and volume fluctuations, and the market prices of securities have been highly volatile. These fluctuations are often unrelated to operating performance and may adversely affect the market price of our shares of common stock. 41 Potential future sales pursuant to registration rights granted by the Company and under Rule 144 may depress the market price for our shares of common stock. The Company has granted a number of its stockholders’ registration rights with respect to their shares of common stock. See the section titled “Registration Rights.” Such future sales of our shares of common stock by our existing stockholders, pursuant to and in accordance with the provisions of any registration statement, may have a depressive effect on the market price of our shares of common stock. Further, in general, under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), a person who has satisfied a minimum holding period of between six months and one-year and any other applicable requirements of Rule 144, may thereafter sell such shares publicly. A significant number of our currently issued and outstanding shares of common stock held by existing stockholders, including officers and directors and other principal stock